Abiomed‘s Impella left ventricular assist device, an endovascular percutaneously-delivered LVAD, will soon be getting a more powerful new model. The current model is capable of delivering an augmentation of cardiac output by up to 2.5 liters a minute, but the new Impella cVAD should do around 3.5 L/m, and possibly up to 4 L/m in the not too distant future.
The new device, and above numbers, were announced at Abiomed’s investor day conference and the company hopes to have the device available to clinicians by the Summer of 2012.
Here are the bullet points about Impella cVAD that were provided to us by Abiomed:
- Percutaneous, Left-Side support platform
- Higher level of hemodynamic support for the Cath Lab
- Peak Flow > 3+ L/min
- Roadmap to increase to > 4L/min
- 9 Fr catheter / 14 Fr pump
- U.S. commercial availability Summer 2012
Morningstar’s coverage of Abiomed’s investor day announcements: Abiomed Analyst Day Reveals Pipeline Potential, Reinforces Positive Moat Trend Rating
Link: Abiomed homepage…
Flashbacks: Impella news on Medgadget…
*This blog post was originally published at Medgadget*